Here is the link for the full text:Further development of clinical microbial transplantation programs can create new opportunities to address important questions central to mucosal immunology and clinical medicine. We can see some of these opportunities potentially arising from our current work with recurrent CDI. Patients with inflammatory bowel disease are at increased risk for contracting CDI.25 So far, among our refractory CDI patients, there seems to be an increased prevalence of patients with Crohn's disease and microscopic colitis. This opens the door to numerous questions, including: Could fecal transplantation have an impact on its underlying inflammatory bowel disease? What will be the fate of the new microbiota over the long term? How do the new microbiota affect overall health and weight gain? Will the composition evolve differently from that seen in patients without discernible underlying intestinal inflammation? Investigating complex patients such as these could provide some interesting pilot data.
A more direct approach to test the therapeutic potential of fecal transplantation for some diseases may also be justifiable, and accompanied by basic investigations. In 1989, Bennet and Brinkman26 described a case report of the successful treatment of refractory ulcerative colitis by fecal bacteriotherapy following antibiotic “sterilization.” Borody et al. published a case series of six patients with refractory ulcerative colitis who have apparently achieved complete (clinical and histological), medication-free, remission using a similar procedure. No disease recurrence was noted in 1–13 years of follow-up.27 However, no follow-up controlled trials have yet emerged, and similar to fulminant CDI, the standard care for refractory ulcerative colitis remains surgical removal of the colon. Nevertheless, replacement of the host's intestinal microbiota by fecal transplantation following deliberate antibiotic treatment and durable persistence of donor bacteria for up to 24 weeks has recently been documented.28 This provides evidence for the plausibility of using this therapeutic approach for conditions that may be caused by the pathogenic microbiota.
http://www.nature.com/mi/journal/v4/n1/ ... 1079a.html